Clinical Trials

Clinical Trials

Articles

Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma
Jonathan Cebon, Elke Jäger, Mark J. Shackleton, Peter Gibbs, Ian D. Davis, Wendie Hopkins, Sharen Gibbs, Qiyuan Chen, Julia Karbach, Heather Jackson, Duncan P. MacGregor, Sue Sturrock, Hilary Vaughan, Eugene Maraskovsky, Antje Neumann, Eric Hoffman, Mathew L. Sherman, and Alexander Knuth
Cancer Immun 2003 3:7

---

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA
Danielle Liénard, Donata Rimoldi, Marie Marchand, Pierre-Yves Dietrich, Nicolas van Baren, Christine Geldhof, Pascal Batard, Philippe Guillaume, Maha Ayyoub, Mikaël J. Pittet, Alfred Zippelius, Katharina Fleischhauer, Ferdy Lejeune, Jean-Charles Cerottini, Pedro Romero, and Daniel E. Speiser
Cancer Immun 2004 4:4

---

The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
Mark Shackleton, Ian D. Davis, Wendie Hopkins, Heather Jackson, Nektaria Dimopoulos, Tsin Tai, Qiyuan Chen, Phillip Parente, Michael Jefford, Kelly-Anne Masterman, Dania Caron, Weisan Chen, Eugene Maraskovsky, and Jonathan Cebon
Cancer Immun 2004 4:9

---

Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded
Krasimira Todorova, Irena Ignatova, Stoyan Tchakarov, Iskra Altankova, Serguei Zoubak, Stanimir Kyurkchiev, and Milcho Mincheff
Cancer Immun 2005 5:1

---

Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma
Andrew M. Scott, Zhanqi Liu, Carmel Murone, Terrance G. Johns, Duncan MacGregor, Fiona E. Smyth, Fook-Thean Lee, Jonathan Cebon, Ian D. Davis, Wendie Hopkins, Angela J. Mountain, Angela Rigopoulos, Nobuo Hanai, and Lloyd J. Old
Cancer Immun 2005 5:3

---

Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination
Qiyuan Chen, Heather Jackson, Mark Shackleton, Phillip Parente, Wendie Hopkins, Sue Sturrock, Duncan MacGregor, Eugene Maraskovsky, Tsin Yee Tai, Nektaria Dimopoulos, Kelly-Anne Masterman, Tina Luke, Ian D. Davis, Weisan Chen, and Jonathan Cebon
Cancer Immun 2005 5:5

---

Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn
Kevin P. O'Boyle, Susan Coatsworth, Gillian Anthony, Mark Ramirez, Edward Greenwald, Ronald Kaleya, Jacob J. Steinberg, Janice P. Dutcher, and Peter H. Wiernik
Cancer Immun 2006 6:5

---

T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein
Akiko Uenaka, Hisashi Wada, Midori Isobe, Takashi Saika, Kazuhide Tsuji, Eiichi Sato, Shuichiro Sato, Yuji Noguchi, Ryohei Kawabata, Takushi Yasuda, Yuichiro Doki, Hiromi Kumon, Keiji Iwatsuki, Hiroshi Shiku, Morito Monden, Achim A. Jungbluth, Gerd Ritter, Roger Murphy, Eric Hoffman, Lloyd J. Old and Eiichi Nakayama
Cancer Immun 2007 7:9

---

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
Ian D. Davis, Gregory A. Wiseman, Fook-Thean Lee, Denise N. Gansen, Wendie Hopkins, Anthony T. Papenfuss, Zhanqi Liu, Timothy J. Moynihan, Gary A. Croghan, Alex A. Adjei, Eric W. Hoffman, James N. Ingle, Lloyd J. Old and Andrew M. Scott
Cancer Immun 2007 7:13

---

LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer
Armin Bender, Julia Karbach, Antje Neumann, Dirk Jäger, Salah E. Al-Batran, Akin Atmaca, Eckhart Weidmann, Melina Biskamp, Sacha Gnjatic, Linda Pan, Eric Hoffman, Lloyd J. Old, Alexander Knuth and Elke Jäger
Cancer Immun 2007 7:16

---

Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer
Christina Lönnroth, Marianne Andersson, Annette Arvidsson, Svante Nordgren, Hans Brevinge, Kristina Lagerstedt and Kent Lundholm
Cancer Immun 2008 8:5

---

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma
Jianda Yuan, Geoffrey Y. Ku, Humilidad F. Gallardo, Francesca Orlandi, Gregor Manukian, Teresa S. Rasalan, Yinyan Xu, Hao Li, Shachi Vyas, Zhenyu Mu, Paul B. Chapman, Susan E. Krown, Katherine Panageas, Stephanie L. Terzulli, Lloyd J. Old, Alan N. Houghton and Jedd D. Wolchok
Cancer Immun 2009 9:5

---

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials
Jedd D. Wolchok, Jeffrey S. Weber, Omid Hamid, Celeste Lebbé, Michele Maio, Dirk Schadendorf, Veerle de Pril, Kevin Heller, Tai-Tsang Chen, Ramy Ibrahim, Axel Hoos and Steven J. O'Day
Cancer Immun 2010 10:9

---

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma
David Berman, Susan M. Parker, Jonathan Siegel, Scott D. Chasalow, Jeffrey Weber, Susan Galbraith, Stephan R. Targan and Hanlin L. Wang
Cancer Immun 2010 10:11

---